CLINICAL IMMUNOBIOCHEMICAL MARKERS IN OPTIMIZING THE DIAGNOSTICS OF BRONCHIAL ASTHMA IN COMORBIDITY WITH TYPE 2 DIABETES MELLITUS

dc.contributor.authorFaizullaeva N. Ya.
dc.contributor.authorMukhtorov Sh. M.
dc.contributor.authorRaufov A. A.
dc.date.accessioned2025-12-28T10:43:49Z
dc.date.issued2025-11-13
dc.description.abstractThe relevance of the study is due to the high frequency of bronchial asthma (BA) and type 2 diabetes mellitus (T2DM), which mutually aggravate each other. The aim of the study was to investigate clinical and immunobiochemical markers to optimize the diagnosis and assess the severity of BA combined with T2DM.
dc.formatapplication/pdf
dc.identifier.urihttps://usajournals.org/index.php/1/article/view/1362
dc.identifier.urihttps://asianeducationindex.com/handle/123456789/4115
dc.language.isoeng
dc.publisherModern American Journals
dc.relationhttps://usajournals.org/index.php/1/article/view/1362/1442
dc.rightshttps://creativecommons.org/licenses/by/4.0
dc.sourceModern American Journal of Medical and Health Sciences; Vol. 1 No. 8 (2025); 51-63
dc.source3067-803X
dc.subjectBronchial asthma, type 2 diabetes mellitus, cytokines, endothelin-1, glycated hemoglobin, comorbidity, immunobiochemical markers.
dc.titleCLINICAL IMMUNOBIOCHEMICAL MARKERS IN OPTIMIZING THE DIAGNOSTICS OF BRONCHIAL ASTHMA IN COMORBIDITY WITH TYPE 2 DIABETES MELLITUS
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typePeer-reviewed Article

item.page.files

item.page.filesection.original.bundle

pagination.showing.labelpagination.showing.detail
loading.default
thumbnail.default.alt
item.page.filesection.name
ya_2025_clinical_immunobiochemical_markers_in_op.pdf
item.page.filesection.size
592.95 KB
item.page.filesection.format
Adobe Portable Document Format

item.page.collections